Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Anne Kroman Added: 2 weeks ago
In this expert interview, Dr Anne Kroman (Medical University of South Carolina, Charleston, US) explores why sex differences in electrophysiology still matter in 2026 and how they should shape clinical decision-making. Focusing on atrial fibrillation (AF) and device therapy, she discusses where women are still underdiagnosed or referred too late, and how to approach ablation and device selection… View more
Author(s): Valentina Kutyifa , Kamala Tamirisa Added: 2 weeks ago
Prof Valentina Kutyifa (University of Rochester, Rochester, MA, US) and Dr Kamala Tamirisa (UT Southwestern Medical Center, Dallas, TX, US) join us to explore the clinical challenges of device therapy selection in patients with competing indications, sharing practical frameworks for navigating this increasingly prevalent scenario in contemporary electrophysiology practice.As the complexity of… View more
Author(s): Usha B Tedrow Added: 2 weeks ago
Dr Usha Tedrow (Brigham and Women's Hospital, Boston, MA, US) discusses contemporary approaches to VT ablation in patients with complex and high-risk substrates, from preprocedural planning and mapping strategy through to long-term management.Interview Questions:How has the approach to VT ablation in high-risk substrates evolved over recent years, and what factors define a patient as high-risk… View more
Author(s): Christopher F Liu Added: 2 weeks ago
HRS 2026 — This expert interview with Dr Christopher F. Liu (Weill Cornell Medicine / NewYork‑Presbyterian Hospital, New York, NY, USA) focuses on how AF ablation strategy is changing with widespread adoption of pulsed field ablation (PFA). Dr Liu discusses how he individualises energy selection between PFA, high‑power short‑duration RF and cryo based on AF mechanism, atrial substrate and patient… View more
Author(s): Ulrich Schotten Added: 1 month ago
HRS Congress 2026 — Prof Ulrich Schotten (Maastricht University, Maastricht, NL) joins us to discuss new findings from the NOAH-AFNET 6 trial examining the distribution of atrial fibrillation burden, its relationship to clinical outcomes, and the effectiveness and safety of anticoagulation based on device reports.NOAH-AFNET 6 (Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial… View more